S828
Clinical - Lung
ESTRO 2026
Proffered Paper 3912
Same-day Sim-Plan-and-Treat SFSABR for ELC is feasible. Patients and staff were generally very satisfied with the service. This is a valuable treatment option for selected patients where multiple hospital visits are a barrier to treatment. References: 1.Ball D et al. Lancet 2019. DOI: 10.1016/S1470- 2045(18)30896-92.Videtic et al. IJROBP 2015. DOI: 10.14016/j.ijrobp.2015.07.22603.Singh et al. IJROBP 2019. DOI: 10.1016/j.ijrobp.2019.08.019 Keywords: Same-day Sim and Treat SABR, PROs Poster Discussion 3901 The role of thoracic radiotherapy in ES - SCLC in ICI era: preliminary results of STHORI trial Giulia Lezzi 1,2 , Elisa Ciurlia 3 , Matteo Sepulcri 1 , Angela Grassi 4 , Bianca Santo 3 , Giuseppe Di Paola 3 , Maria Cristina Barba 3 , Elisa Cavalera 3 , Paola De Franco 3 , Sara De Matteis 3 , Giulia Gobitti 5,1 , Giulia Gulino 5,1 , Angela Leone 3 , Antonella Papaleo 3 , Chiara Paronetto 1 , Donatella Russo 3 , Angela Sardaro 3 , Marco Krengli 1,6 1 Department of Radiotherapy, Veneto Institute of Oncology-IRCSS, Padua, Italy. 2 University Hospital of Padua, versity of Padua, Padua, Italy. 3 Department of Radiotherapy, Vito Fazzi Hospital, Lecce, Italy. 4 Clinical Department of Research Unit, Veneto Institute of Oncology-IRCSS, Padua, Italy. 5 University Hospital of Padua, University of Padua, Padua, Italy. 6 Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy
Single-fraction SABR for primary NSCLC and lung oligometastases: a pooled analysis of 1691 patients Neil D Wallace 1 , Kevin Stephans 2 , Mark Farrugia 3 , Mathias Bressel 4 , Gregory Videtic 2 , Anurag Singh 3 , Austin Iovoli 3 , Nadia Malik 3 , Susan Harden 1,5 , Nikki Plumridge 1,5 , Shankar Siva 1,5 1 Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 2 Radiation Oncology, Cleveland Clinic Cancer Center, Cleveland, OH, USA. 3 Radiation Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 4 Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia. 5 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia Purpose/Objective: Landmark randomised studies comparing single- fraction with fractionated SABR have identified similar efficacy and adverse event rates in the setting of primary NSCLC (1,2) and pulmonary oligometastases (3). We proposed to retrospectively review the SABR databases at the three institutions which led these randomised trials to combine efficacy and adverse events data for a large population treated with single- fraction SABR for primary NSCLC and pulmonary oligometastases. Material/Methods: Population: Adult patients ( ≥ 18 years old) treated with SABR for primary NSCLC or pulmonary metastases at Roswell Park Comprehensive Cancer Centre, the Cleveland Clinic and Peter MacCallum Cancer Centre between September 2008 and December 2022.A retrospective review of all clinical, radiological and histological encounters within each institution’s electronic medical record was performed by local investigators. Outcomes including local/distant failure, survival, and adverse events were recorded. The anonymised data was pooled and analysed centrally. Results: 1691 patients were included. Median follow-up was 51 months. Median age was 73.1 (IQR 66.0-79.3), 834 (49%) were male, and 992 (68%) were medically inoperable. Median maximum tumour dimension was 17.0mm (IQR 12.0-23.0). The most frequent prescription doses were 34Gy (39%), 30Gy (23%) and 28Gy (17%); range 26-34Gy.1201 (71%) were treated for primary NSCLC. Median age was 75.0 (IQR 69.0- 80.8) and ECOG performance status was 0 (26%), 1 (54%), 2 (18%), 3 (2%). Histological confirmation was obtained for 880 (74%) with 446 (51%) adenocarcinoma, 301 (34%) squamous cell. 490 (29%) had pulmonary oligometastases. Median age was 68.0 (IQR 59.0-75.0) and ECOG was 0 (59%) or 1 (33%) in most cases. The most frequent histologies were
Made with FlippingBook - Share PDF online